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Background: Genetic regulation of plasma lipids has been shown to inﬂuence the risk of coronary artery
disease (CAD).We analyzed the relationship between rs599839 and rs646776 single nucleotide polymor-
phisms (SNPs) present in the CELSR2–PSRC1–SORT1 gene cluster, candidate gene expression, and their
associationwith CAD and circulating lipid levels in a representative cohort of Asian Indians selected from
the Indian Atherosclerosis Research Study.
Methods: SNPs rs599839and rs646776were genotypedbyTaqmanassay in1034CADpatients (cases) and
1034 age- and gender-matched controls. Expression of CELSR2, PSRC1, and SORT1 genes wasmeasured in
100 cases and 100 controls. Plasma levels of total cholesterol (TC), triglycerides, high-density lipoprotein-
cholesterol, and low-density lipoprotein-cholesterol (LDL-c) were measured by enzymatic assay.
Results: Both rs646776 and rs599839 were in strong linkage disequilibrium (r=0.98) and showed signif-
icant protective association with CAD (OR=0.315, 95% CI 0.136–0.728, p<0.007 and OR=0.422, 95% CI
0.181–0.981, p=0.045, respectively). Haplotype TA showed 72% frequency and was associated with CAD
(OR 0.77, 95% CI 0.67–0.88, p=0.0002). PSRC1 gene expressionwas lower in the cases than in the controls
−4(0.75±0.405 versus 1.04±0.622, p=2.26×10 ). The homozygous variant and heterozygous genotypes
showed 30% and 15% higher PSRC1 expression, respectively. Correspondingly, the minor alleles were
associated with lower plasma TC and LDL-c levels.
Conclusion: PSRC1 in the cholesterol gene cluster shows a signiﬁcant association with CAD by virtue of
the two SNPs, rs646776 and rs599839 that also regulate plasma cholesterol levels.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
Coronary artery disease (CAD) is reported to be one of the lead-
ng causes of death in young Indians in the 30–50 year age group
1]. Identiﬁcation of predisposing genetic factors that promote the
evelopment of premature CAD should eventually help in reducing
he overall mortality rates by promoting targeted therapy. In this
egard, genome wide association studies (GWAS) in diverse ethnic
opulations have been instrumental in the discovery of numerous
enetic variants for CAD [2–4] in addition to conﬁrming previously
dentiﬁed markers like those in the 9p21 locus [3,4]. Apart from
∗ Corresponding author at: Mary and Garry Weston Functional Genomics Unit,
hrombosis Research Institute, Narayana Hrudayalaya 258/A, Bommasandra Indus-
rial Area, Anekal Taluk, Bangalore 560099, Karnataka, India. Tel.: +91 80 27835303;
ax: +91 80 27835302.
E-mail address: jayashreeshanker@triindia.org.in (J. Shanker).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.012
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights retraditional risk factors such as age, hypertension, and diabetes,
heritable factors such as genes that regulate plasma lipid levels
underscore the signiﬁcant role of lipids in the development of CAD
[5,6]. Studies have identiﬁed single nucleotide polymorphisms
(SNPs) in novel genetic regions that affect plasma lipid levels [7–9]
and some of those SNPs reside within putative candidate genes
that are known to regulate the lipid metabolism [10,11].
The gene cluster, located on chromosome 1p13.3 region (in
Homo sapiens) comprises three distinct genes, CELSR2 (cadherin,
EGF LAG seven-pass G-type receptor 2), PSRC1 (proline/serine rich
coiled coil 1), and SORT1 (sortilin 1). The CELSR2 gene encodes
a non-classic type of cadherin involved in contact-mediated cell
adhesion and receptor–ligand interactions [12]. The PSRC1 gene
product plays a role in microtubule destabilization [13] while the
SORT1 gene encodes for the sortilin protein that plays an impor-
tant role in the uptake of lipids [14]. A variant, rs599839 was
initially identiﬁed through GWAS study in the intergenic region
served.
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etween CELSR2 and PSRC1 and was associated with increased
isk of CAD [15]. Subsequently, variants in this cholesterol gene
luster (rs646776 and rs599839) have been associated with low
ow-density lipoprotein cholesterol (LDL-c) levels [8,16]. Further,
recent replication study conducted on Asian Indians from the
ikh Diabetes Study (SDS) cohort reported a signiﬁcant associa-
ion between variants in the lipid regulating gene loci and the lipid
roﬁles including high-density lipoprotein cholesterol (HDL-c) and
riglyceride (TG) levels [17]. These studies highlight the signiﬁcant
ole played by these SNPs and emphasize the need to replicate
hese ﬁndings in other populations with the possibility of trans-
ating these ﬁndings into clinically meaningful outcomes. We have
xamined the associationof twoSNPs, rs599839and rs646776with
AD, the expression of CELSR2, PSRC1, and SORT1 genes and fasting
ipid levels in a representative cohort of Asian Indians.
aterials and methods
tudy population
The study subjects (cases and controls) were selected from
he ongoing Indian Atherosclerosis Research Study (IARS), an epi-
emiological study that was initiated in January 2004 with the
bjective of understanding the contributions of traditional and
merging risk factors of premature CAD in Asian Indians residing
n the Indian sub-continent. The design and overview of the IARS
ave been previously published [18]. Brieﬂy, CAD patients were
nrolled from two major cardiology specialty hospitals, Narayana
ealth, Bangalore and the Asian Heart Institute and Research Cen-
er, Mumbai as well as from the local clinics/hospitals in Bangalore
etween 2004 and 2011. CAD patients had a strong family his-
ory of cardiovascular disease, with males having age at CAD onset
60 years and females <65 years. Presence of CAD was based on
he report of cardiologists’ diagnosis and included any of the fol-
owing criteria – angiographically conﬁrmed presence of disease,
ith/without history of myocardial infarction and treated with
tandardmedications, percutaneous coronary intervention (PCI), or
oronary angiography bypass graft (CABG). Controls werematched
or gender and age (±3 years) and were enrolled from the same
eographical area as that of the cases. They were healthy, clinically
symptomatic for CAD, showed normal electrocardiography (ECG)
eadings anddidnothave a familyhistoryof cardiovascular disease.
ll the participants were above 18 years, with family living in the
ndian sub-continent for at least two generations, did not have any
thermajor illness such as cancer, liver disease, or primordial heart
iseases such as cardiomyopathies or congenital heart disease, and
ere free of concomitant infections such as cold and cough at the
ime of enrolment. Written informed consent was obtained from
ll the participants. The IARS protocol has been approved by the
hrombosis Research Institute Ethics committee and is based on
he bioethics guidelines of the Indian Council of Medical Research
19]. A total of 1034 cases and 1034 age- and gender-matched con-
rols, were selected for the association study, while an additional
00 cases and 100 controls were included for the gene expression
tudy.
ample preparation
Venous blood samples were collected after an overnight fast
rom all the study participants. Aliquots of serum and plasma
ere stored at −80 ◦C. Genomic DNA was extracted by a modi-
ed salting out procedure [20]. Total RNAwas extracted from fresh
mlethylenediaminetetraacetic acidwholebloodsampleusing the
IAmp RNA blood mini kit (Qiagen, Valencia, CA, USA), following
anufacturer’s instructions. BothgenomicDNAand total RNAwereology 64 (2014) 339–346
quantitated using NanoDrop ND-1000 Spectrophotometer (Nano-
Drop, Wilmington, DE, USA). RNA samples were further digested
with DNase I followed by ﬁrst strand synthesis of cDNA using the
cDNA Archive kit (Applied Biosystems, Foster City, CA, USA).
Lipid assays
Serum total cholesterol (TC) and TGwere estimated by standard
enzymatic analysis on the Cobas-Fara II Clinical Chemistry Auto
analyzer (F. Hoffman La Roche Ltd., Basel, Switzerland). HDL-c
concentrations were estimated after precipitating the non-HDL
fractions with a mixture of 2.4-mmol/l phosphotungstic acid and
39mmol/l magnesium chloride (Bayer Diagnostics, Gujarat, India).
Plasma LDL-c was calculated using the Friedewald formula [21].
The inter-assay co-efﬁcient of variation for the commercial con-
trols and normal serum pool ranged from 4.9% to 7.0% for TC, 6.1%
to 7.7% for TG, and 7.1% to 12.2% for HDL-c.
The atherogenic index of plasma (AIP) was estimated using the
formula [AIP = log(TG/HDL-c)] [22]. Subjects were classiﬁed into
three groups based on their AIP scores as follows: Group 1 (low
atherogenic risk): <0.011; Group 2 (intermediate risk): 0.11–0.21;
Group 3 (high risk): >0.21. Further, all the participants in the asso-
ciation cohort were classiﬁed into those with or without metabolic
syndromebased on standardAdult Treatment Panel (ATP) III guide-
lines (National Cholesterol Education Program-ATP-III, 2001) [23]
as well as modiﬁed ATPIII criteria [24]. The primary difference
between the two methods of classiﬁcation is that abdominal obe-
sity deﬁned by waist circumference of WC >102 cm (40 in.) in men
and >88 cm (35 in.) in women was revised to >90 cm for men and
>80 cm for women based on publications that have shown that the
revised cut-offs represent abdominal obesity better for the Asian
Indian population due to their unique pattern of fat distribution
[25].
Genotyping of CELSR2–PSRC1–SORT1 variants
Two SNPs in the CELSR2–PSRC1–SORT1 gene loci namely
rs646776 and rs599839were genotypedbyTaqManallelic discrim-
ination assay on a 7900HT Fast Real Time PCR instrument (Applied
Biosystems). In-house controls with known genotype were used
as positive control while a no-template reaction was assigned
as the negative control and run with every batch of Taqman
assay.
Gene expression assay
Expression levels of CELSR2, PSRC1, and SORT1 genesweremea-
sured using Taqman real-time PCR assay. The FAM and TAMRA
dye labeled probe-primer mix (20×) and the Universal Master Mix
(2×) were purchased from ABI (Applied Biosystems). -Actin was
used as an endogenous control and run along with every sample.
All assays were done in duplicates and according to manufac-
turer’s instructions. Data were processed using SDS v2.3 (sequence
detection software) (Applied Biosystems). RQManagerwas used to
calculate the relative changes in mRNA expression levels between
the cases and the controls. The assaywas repeated in duplicates for
samples showing skewed expression pattern while the persistent
outliers were excluded from further analysis.
Network analysis
We generated a protein interaction network with the
PSRC1 as seed gene using the software Search Tool for the
Retrieval of Interacting Genes/Proteins (STRING) version 9.05
(http://string-db.org) [26,27] in order to identify its interacting
partners.
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tatistical methods
Statistical analysis was done using SPSS v17.0 software (SPSS
nc., Chicago, IL, USA). Continuous variables were expressed as
ean± standard error of the mean (SEM). Chi-square test was
sed for testing the association of CELSR2–PSRC1–SORT1 vari-
nts with CAD and for estimating the odds ratios (ORs) and
5% conﬁdence intervals (CIs), while Student’s t-test and uni-
ariate analysis were used to test for the mean differences
n the expression levels and other quantitative traits between
he cases and the controls. Age, gender, diabetes, hyperten-
ion, plasma lipids, body mass index (BMI) and smoking were
onsidered as covariates and appropriately adjusted for during
ultivariate analysis to test for the association of the two SNPs
ith plasma lipid levels. SNPstats online software was also used
o calculate allele and genotype frequencies, Hardy–Weinberg
quilibrium and genotype/haplotype associations with CAD
http://bioinfo.iconcologia.net/SNPstats) [28]. Estimation of link-
ge disequilibrium (LD) was performed using the Haploview v3.32
oftware (http://www.broad.mit.edu/mpg/haploview) [29].
esults
linical characteristics of study participants
The clinical proﬁle of subjects enrolled in (a)
enotype–phenotype association study and (b) gene expres-
ion study is summarized in Table 1. In the gene expression study
ohort, after removal of outliers and individuals with missing
nformation, data on 98 cases and 97 controls were included in the
nal analysis. Males showed higher representation (76–92%) than
emales (24–8%). The average age of the cases and the controls
able 1
linical characteristics of study participants included in the association and expression st
Association study cohort
Cases (n=1034) Control (n=1034)
Clinical factors
Age (years)a 50.13±0.261 50.13±0.252
Age at onset (years)a
Males, N (%) 801(77.5%) 785 (75.9%)
Females, N (%) 233 (22.5%) 249 (24.1%)
BMI (kg/m2)a 25.97±0.13 25.47±0.13
Waist circumference (cm)a 89.90±0.327 90.48±0.362
Waist/hip ratio (cm)a 0.95±0.003 0.95±0.002
Laboratory studies
TC (mg/dl)a 152.42±1.33 176.71±1.209
TG (mg/dl)a 165.55±2.41 167.04±3.88
HDL-c (mg/dl)a 37.52±0.27 40.30±0.317
LDL-c (mg/dl)a 81.79±1.146 104.62±1.012
Medical history
Smoking, N (%) 406 (39.3) 232 (22.5)
Hypertension, N (%) 557 (54) 156 (15.3)
Diabetes mellitus, N (%) 450 (43.6) 164 (16.1)
Metabolic syndrome
MS-ATPIII 205 (19.8) 221 (21.4)
MS-modiﬁed ATPIII 556 (53.8) 499 (48.3)
Medicationsb
Statin, N (%) 775 (75) 2 (0.5)
Fenoﬁbrates, N (%) 20 (1.93) –
Beta blockers 660 (63.83) –
ACE-inhibitors 329 (31.82) –
Calcium-channel blockers 285 (27.56)
Nitrates 377 (36.46) –
Antiplatelets 790 (76.40) 1 (0.09)
Hypoglycemic agents 201 (19.44) –
MI, bodymass index; FBS, fasting blood sugar; HDL-c, high-density lipoprotein cholester
reatment Panel; TC, total cholesterol; TG, triglycerides.
a Continuous variables are expressed as mean± standard error.
b Information on medication was missing for 1 case in the association study cohort andology 64 (2014) 339–346 341
and the age at onset of CAD were around 50 years. Classical risk
factors such as diabetes and hypertension were more prevalent in
the cases than in the controls. Measurement of waist–hip ratio and
measurement of waist circumference were comparable between
the two groups whereas the mean BMI (kg/m2) was signiﬁcantly
higher in cases as compared to the controls in the association study
cohort (25.97±0.13kg/m2 versus 25.47±0.13kg/m2, p=0.008).
TC and LDL-c levels were found to be lower in the cases than in the
controls, which might be due to the usage of statins in the former
group.
In the association study cohort, there were 464 cases of chronic
stable angina (CSA), 61 with unstable angina (UA), and 482 cases
with myocardial infarction (MI). Information was not available
for 27 cases. Severity of CAD based on the number of diseased
vessels showed the following distribution: 1-vessel disease: 186;
2-vessel disease: 278; 3- or more vessel disease: 501; data miss-
ing: 69. With regard to medical management of CAD, 169 patients
underwent PCI, 692 patients underwent CABG, while 173 were
only on standard drug therapy. Medication details are provided in
Table 1 and primarily include statins, beta-blockers, angiotensin-
converting enzyme inhibitors, calcium-channel blockers, nitrates,
antiplatelets, fenoﬁbrates, and hypoglycemic agents.
In the gene expression study cohort, there were 51 cases of CSA
and 46 cases of MI. Information was missing for 4 cases. Frequency
distribution values based on the number of diseased vessels were
given as follows: 1-vessel disease: 10; 2-vessel disease: 33; 3- or
more vessel disease: 53; data not available: 5 cases. 88 patients
underwent CABG; three had PCI while nine patients were treated
with standard medication only. As there is a restricted access to
the old patient records at Narayana Health due to the ongoing pro-
cess of digitization of hospital records, we have been unable to
retrieve medical information for all the participants. Further, as
udy.
p-Value Gene expression study cohort p-Value
Cases (n=98) Control (n=97)
0.711 50.13±0.651 49.88±0.651 0.780
48.56±0.740 –
– 82 (84.5) 89 (91.7) –
– 16 (16.49) 8 (8.2) –
0.008 24.82±0.394 24.43±0.392 0.491
0.234 89.51±0.899 91.13±0.904 0.205
0.19 0.99±0.006 0.98±0.006 0.287
9.74×10−4 129±3.89 179±3.87 1.86×10−16
0.744 154.75±9.11 194.71±9.06 0.002
4.244×10−11 31.02±1.028 37.84±1.023 5.02×10−6
1.12×10−47 68.30±3.29 103.87±3.35 1.79×10−12
8.96×10−17 59 (62.1) 25 (26.3) 5.50×10−7
2.98×10−14 38 (39.6) 11 (11.5) 5.76×10−6
1.92×10−43 49 (51) 17 (17.7) 8.87×10−7
0.415 33 (32.7) 39 (40.6) 0.300
0.014 42 (41.6) 55 (57.3) 0.033
– 53 (56.7) – –
– – – –
– 58 (57.43) – –
– 30 (30) – –
– 8 (8) – –
– 42 (42) – –
– 51 (51) – –
– 8 (8) – –
ol; LDL-c, low-density lipoprotein cholesterol; MS, metabolic syndrome; ATP, Adult
1 case in the gene expression study cohort.
3 Cardiology 64 (2014) 339–346
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Fig. 1. Linkage disequilibrium plot for rs646776 and rs599839 SNPs in the 1p13.3
′
(r=0.18, p=0.013).
Table 2
Mean plasma lipid levels for rs646776 and rs599839 SNPs in the association study.
rs646776
CC TC TT p-Value
TC (mg/dl) 155.68 163.35 166.60 0.007
TG 150.63 169.03 166.50 0.131
HDL-c 38.52 39.41 38.6 0.172
LDL-c 87.38 90.99 95.21 0.006
rs599839
AA AG GG p-Value
TC (mg/dl) 166.75 163.15 156.13 0.007
TG 166.91 168.74 149.94 0.10642 P. Arvind et al. / Journal of
ome of the patients underwent angiogram procedure or percu-
aneous interventional surgery elsewhere and came to Narayana
ealth for a general consultation, we were unable to procure rele-
ant test records from such patients.
The AIP was estimated for all study participants. In the associa-
ion study cohort, themeanAIPwas signiﬁcantly higher in the cases
0.614) than in the controls (0.557) (p=1.26×10−6). Mean AIP was
igher in the males (n=1572) (0.608) than in the females (n=478)
0.608 versus 0.515, p=4.18×10−11). There was a signiﬁcant asso-
iation between three AIP groups and CAD (p=1.29×10−12) and
he percent frequencies in the cases and controls were as follows:
ow risk: 1.3% and 4.9%; intermediate risk: 1.6% and 6.5%; high risk:
7.0% and 88.6%. Logistic regression showed an OR of 3.988 (95%
I 2.011–7.909) for CAD when the 1st and 3rd groups were com-
ared after adjusting for age, gender, diabetes, and hypertension.
igniﬁcant higher mean AIP values were noted in the cases in spite
f 73.4% of the cases being on statin medication while only 0.5% of
he controls were on any lipid-lowering drug.
The overall trend was similar in the gene expression cohort;
owever the differences or association was not statistically signif-
cant possibly due to the small sample size.
In the association study cohort of 2068 subjects, there was no
igniﬁcant difference in the proportion of subjects with metabolic
yndrome (MS) in the cases (n=205, 19.8%) and the controls
n=221, 21.4%) (p=0.415) when standard ATPIII guidelines were
pplied. However, the pattern changed with the application of the
evised WC cut-offs where the cases had higher proportion of MS
n=556, 53.8%) than among the controls (n=499, 48.3%) (p=0.014).
In the gene expression study cohort, MS information was avail-
ble for 100 cases and 96 controls. While the standard ATPIII
lassiﬁcation did not show any signiﬁcant difference in the preva-
ence of MS in the cases (n=33, 32.7%) and the controls (n=39,
0.6%) (p=0.300),with the revisedATPIII,MSprevalencewas inter-
stingly higher in the controls (n=55, 57.3%) than in the cases (42,
1.6%) (p=0.033).
ssociation of SNPs with CAD
rs646776 and rs599839 SNPs in the CELSR2–PSRC1–SORT1 gene
oci were in Hardy–Weinberg equilibrium in the control group
p>0.05). rs599839 (OR=0.315, 95% CI 0.136–0.728, p<0.007) and
s646776 (OR=0.422, 95%CI 0.181–0.981, p=0.045) showed signif-
cant protective association with CAD and were in strong LD with
ach other (r=0.98) (Fig. 1). The common ‘TA’ haplotype for the two
ariants, rs646776 and rs599839 showed a frequency of 0.73. The
lternate ‘CG’ haplotype (0.27) showed protection against CAD (OR
.77, 95% CI 0.67–0.88, p=0.0002).
ssociation of SNPs with plasma lipid levels
We examined the effect of rs646776 and rs599839 on plasma
ipid levels. Both variants showed a signiﬁcant association with TC
p=0.007) and LDL-c (p<0.01), with theminor alleles being associ-
ted with lower lipid levels. This association remained signiﬁcant
ven after adjusting for age, gender, diabetes, hypertension, lipids,
MI, and smoking (p<0.002). Homozygotes for the minor allele
CC or GG) showed an overall reduction of approximately 11mg/dl
0.29mmol/l) in TC levels and around 8mg/dl (0.21mmol/l) in
DL-c levels (Table 2).
ssociation between genotype and CELSR2–PSRC1–SORT1 gene
xpressionAs compared to the common TT genotype in rs646776 or AA
enotype in rs599839, the homozygous variant genotype (CC or
G) showed 30% increase in PSRC1 mRNA expression while thegene loci. Haploview linkage disequilibrium plot with D value of 98 between the
two SNPs
heterozygote genotypes showed 15% higher expression (Fig. 2).
There was however no signiﬁcant change in the expression levels
of CELSR2 and SORT 1 genes across all the three genotypes.
Association of CELSR2–PSRC1–SORT1 gene expression with CAD
and lipids
Next, we looked at the association of CELSR2–PSRC1–SORT1
gene expression in CAD. Expression levels of PSRC1 gene tran-
script were signiﬁcantly lower in the cases than in the controls
(0.75±0.405 versus 1.04±0.622, p=2.255×10−4). On the other
hand, the expression of CELSR2 and SORT1 genes did not show any
signiﬁcant difference between the cases and the controls. Further,
the PSRC1 gene showed signiﬁcant protective associationwith CAD
(OR=0.216, 95% CI 0.087–0.535, p=0.001). We observed strong
correlation of PSRC1 mRNA expression with SORT1 (r=0.69) and
CELSR2 (r=0.46). PSRC1 expression also showed modest corre-
lation with TC (r=0.22, p=0.003), LDL-c (r=0.17, p=0.024), and
HDL-c (r=0.16, p=0.032) levels while CELSR2 showed correlation
with TC (r=0.22, p=0.003), LDL-c (r=0.18, p=0.011), and TG levelsHDL-c 38.67 39.27 38.74 0.387
LDL-c 95.09 91.15 87.74 0.01
TC, total cholesterol; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol;
LDL-c, low-density lipoprotein cholesterol.
P. Arvind et al. / Journal of Cardiology 64 (2014) 339–346 343
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network generated using STRING v9.05, with PSRC1 as the seed
gene, we observed that the PSRC1 appeared to be a key protein
linking CELSR2 and SORT1 on one side and factors affectingmitosis
and cell division on the other side (Fig. 3). Further, the link of PSRC1ig. 2. Mean mRNA expression levels of CELSR2, PSRC1 and SORT1 genes across rs6
he presence of homozygote (major andminor) and heterozygote alleles for rs64677
A: major allele, GG: minor allele.
etwork analysis
A bionetwork was generated using STRING to understand the
elationship of the PSRC1 genewith other interactors where PSRC1
as used as the seed gene. This gene showed interactions with
arious partners including genes involved in lipoprotein uptake
nd transport (SORT1 and SORL1), mitosis (CDCA3 and CDCA8),
nd Golgi transport (KIF20A) while PSRC1 itself is responsible for
icrotubule destabilization and spindle assembly (Fig. 3).
iscussion
Based on the literature search from GWAS, we identiﬁed two
NPs, rs599839and rs646776present in theCELSR2–PSRC1–SORT1
holesterol gene cluster on chromosome 1p13.3 and examined
heir effect on gene expression, association with CAD and cir-
ulating lipid levels in a representative cohort of Asian Indians.
e observed a strong independent association of both the vari-
nts with the disease, lower expression of PSRC1 gene transcript
n the cases and the minor alleles of both SNPs being associ-
ted with lower level of circulating lipids, particularly TC and
DL-c. These two variants that were initially identiﬁed through
WAS in the Caucasian population showed an association with
AD and the lipid phenotype [15,30–32] and have been subse-
uently validated in other populations [33] including the Sikh
iabetes Study cohort [34]. Thus, the most plausible conclu-
ion derived from these reported studies including the present
tudy is that the CELSR2–PSRC1–SORT1 locus exerts its effect
n CAD through a well-established risk factor, namely plasma
DL-c.
It is interesting to note that of the three genes in the above-
entioned cluster, SORT1has been reported to be directly involved
n lipid regulatory metabolism [14,35,36] while the primary role
f CELSR2 and PSRC1 is cell adhesion and cytoskeleton stabiliza-
ion, respectively [13,37]. To the contrary,weobserved a signiﬁcant
ssociation of PSRC1 mRNA expression with CAD as well as the
ssociation of the two SNPs with TC and LDL-c levels in the present
tudy. This was comparable to a report by Wild et al. [38] who
howed a signiﬁcant association of rs599839 SNP with expression
f PSRC1 transcripts in the monocytes and plasma LDL-c levels. A
umber of studies have also shown an association of the variant6 and rs599839 genotypes. mRNA expression level of CELSR2, PSRC1 and SORT1 in
rs599839 SNPs.Note: for rs646776, TT: major allele, CC: minor allele; for rs599839,
alleles of both rs599839 and rs646776 with low plasma LDL-c lev-
els [10,39,40]. In our preliminary analysis of the protein interactionFig. 3. Network analysis with PSRC1 gene as the seed gene. Network constructed
using STRING, a web-based tool with PSRC1 as the protein of interest shows inter-
actions (edges) of PSRC1 with other proteins.
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(BT/01/CDE/08/07). We thank the study participants and the doc-44 P. Arvind et al. / Journal of
ith SORL1 is interesting in that the latter encodes for a sortilin-
elated receptor protein, which is located on chromosome 11q23,
et another important locus regulatingplasma lipids [34]. Fromthis
t appears that the relationship among the candidate genes in the
p13.3 locus is complex and remains to be fully elucidated.
The fact that lipid is an important factor for the development of
therosclerosis is understood from the fact that there was a strong
ssociationof atherogenic index andCAD. Further,MS is considered
o be a precursor for CAD. Asian Indians have a greater predispo-
ition to MS and the need for ethnicity-speciﬁc cut-offs has been
xtensively discussed [25,41,42]. This was evident from the fact
hat there was high MS prevalence both among the cases and con-
rols and the frequency differences in the cases and controls were
tatistically signiﬁcant when the revised cut-off was used for waist
ircumference. Thus both lipids and visceral adiposity appear to
e signiﬁcant factors contributing to the development ofmetabolic
iseases and CAD in this population.
Both rs646776 and rs599839 are located in an intergenic region
etween CELSR2 and PSRC1 genes. SNP rs599839 was identiﬁed
rst to be located in the 3′-untranslated region (UTR) of PSRC1,
nd showed associationwith CAD in the British and German cohort
tudy [43]. Subsequently, ameta-analysis carried out on the British
opulation demonstrated that the rs646776 and rs599839 SNPs
ere signiﬁcantly associated with lower levels of circulating LDL-c
16]. In the present study, which includes a representative cohort
f Asian Indians living in the Indian sub-continent, we observed a
imilar pattern, wherein the minor alleles of both the SNPs were
ssociated with reduced LDL-c levels. This demonstrates a protec-
ive role of both the variant alleles.Wealsonotedhigher expression
f PSRC1 mRNA in the carriers of the minor alleles, C and G. Con-
rary to this, in an earlier study, higher mRNA expression levels of
ORT1 were shown to induce a signiﬁcant cellular uptake of LDL-c
10] and the homozygous minor allele of rs646776 SNP was asso-
iated with 12-fold higher SORT1 and PSRC1 expression in human
iver samples [44]. In fact, this was the ﬁrst study on a series of
uman cohorts and human-derived hepatocytes to provide func-
ional evidence on the association of CELSR2–PSRC1–SORT1 locus
ith CAD.
A non-coding SNP located in the 3′-UTR of angiotensin II type I
eceptor gene has been shown to affect the miRNA-mediated reg-
lation of the mRNA [45], while in the case of human LDL receptor
ene, a SNP present in the 3′-UTR was associated with plasma lipid
evels in Caucasian males [46]. This provides an insight into the
ost-transcriptional regulation brought about by these non-coding
NPs. rs599839 is also a non-coding SNP located in the 3′-UTRof the
SRC1genewhichcouldpossiblyplaya regulatory role at themRNA
evel. Given that the increased expression level of PSRC1 mRNA
ranscripts and the reduced levels of LDL-c and TC were detected
n the presence of minor alleles of both rs599839 and rs646776
NPs, it might indicate a possible role of the PSRC1 gene in the
irect or indirect regulation of plasma lipid levels. The PSRC1 and
ORT1 genes lay in close proximity in the 1p13.3 genomic locus,
hich was reﬂected by the presence of strong correlation in the
ene expression between themicrotubule destabilizing PSRC1 and
lasma lipid regulating SORT1 genes in our study. Furthermore, in
he light of rs646776 and rs599839 SNPs being present as a tight
ntergenic cluster, it would be interesting to understand the under-
ying mechanisms, the functional relationship, and the manner in
hich the PSRC1andSORT1genesmight complement eachother in
odulating CAD risk through their combined effect on cholesterol
etabolism.
A number of GWAS studies have conﬁrmed the consistent yetodest association of the 9p21.3 common variants with incident
AD. There is however an urgent need to identify additional such
ariants that can improve risk prediction. Given the published evi-
ence on the role of these SNPs in modulating PSRC1 expression,ology 64 (2014) 339–346
their protective association with CAD and circulating cholesterol,
it is a matter of time before rs599839 and rs646776 can be consid-
ered asnovel variantswithpotential clinical utility.However,much
workneeds to be done to understand the underlyingmechanismby
which these SNPs actually contribute to the clinical manifestation
of the disease.
We acknowledge some of the limitations of this study. To begin
with, the controls were selected from among individuals who
were clinically asymptomatic for the disease and showed normal
ECG readings. This does not exclude the presence of an under-
lying silent disease. Nonetheless, as the only fool-proof method
to rule out the presence/absence of disease is through a coro-
nary angiogram, which is not ethically feasible in an experimental
setting, this could to some extent have an impact on the signif-
icance of our study ﬁndings. Importantly, our initial ﬁndings on
the association of the two SNPs with CAD have not been vali-
dated in an independent cohort, considering that the contribution
of genetic factors to CAD risk is rather small and is primarily
based on differences in the risk allele frequency in cases versus
controls. In this context it is worthwhile to recall that this locus
retained genome-wide signiﬁcance (>10−8) even after stringent
Bonferroni correction in the Caucasian [47] and other Asian [48]
populations demonstrating the robustness of their association
with CAD, primarily mediated through the lipids [8]. Further, only
one locus, namely CELSR2–PSRC1–SORT1, was considered for this
study while a recent study has identiﬁed around 157 loci associ-
ated with the lipid trait [49]. The predominant usage of statins,
a popular lipid-lowering drug, might to some extent have inﬂu-
enced the outcome of the ﬁndings. However, as the genotype–lipid
association pattern did not change even after the data were strat-
iﬁed according to statin usage, there is no apparent confounding
effect of statins on the outcome. Statins are known to inﬂuence
gene expression, particularly those associated with inﬂamma-
tion [50,51]. Again the gene expression results were comparable
when the data were stratiﬁed based on statins thus alleviating our
concerns.
In conclusion, this pilot study reiterates the involvement of the
CELSR2–PSRC1–SORT1 locus inmodulating the risk of CAD through
hitherto unknown mechanisms that regulate plasma lipid levels.
While the association of the two SNPs, rs646776 and rs599839with
CADand lipids corroboratewithotherpublished studies, PSRC1and
SORT1 appear to be potential gene candidates in the lipid pathway.
However, until the functional relationship among the members of
this cholesterol locus and other reported lipid genes is established,
the true clinical utility of the CELSR2–PSRC1–SORT1 locus will not
be fully realized.
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